Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies.

• DOI: 10.1200/jco.2024.42.4_suppl.446
• Publication Date: 2024-01-29T21:06:41Z
• Authors: Ardit Feinaj; Kaizen Nathani; Amina Touma; Roy Elias; Maximilian Pallauf; Mark Christopher ...; Michael Anthony C...; Nirmish Singla; Yasser Ged
• Keywords: Log-rank test; Progression-free survival

446 Background: Numerous combos of ICIs and Tyrosine Kinase Inhibitors (TKIs) have received approval for the management mccRCC. Specific peripheral blood cell counts reflect inflammation impact anti-tumor immunity, here we investigated their role as biomarkers clinical benefit to ICI in RCC. Methods: We performed a retrospective study 179 mccRCC patients treated with ≥ 4 weeks (2013-2023), where examined baseline 6-week post-treatment Neutrophil Lymphocyte ratio (NLR), Red Distribution Width (RDW), eosinophil values. categorized these values High (H) or Low (L) based on medians. Our analysis included objective response rate (ORR), overall survival (OS), progression-free (PFS), time next treatment (TNT). Kaplan-Meier methods log-rank test were used evaluate from start event interest. Results: 111 eligible ICI-naïve median age 63, 76% male. IMDC risk scores 22% favorable, 53% intermediate, 25% poor risk. Treatment 50 (45%) ICI+ICI therapy duration 6.3 months, 61 (55%) ICI+TKI 8.8 months. In group, OS was 28.2 months (95% CI 20.7-38.4), PFS 5.5 3.7-7.8), TNT 12.7 7.4-20.4). 21.7 17.1-25.4), 7.4 5.6-11.1), 12.5 9.7-16.4). The ORR 38% 56% group (p=0.062). No differences seen NLR. higher RDW levels correlated shorter TNT, while at week 6 longer (significant results highlighted table below). Conclusions: Eosinophil are potentially readily available clinic predicting monitoring combo outcomes patients. Validation larger cohorts is warranted. [Table: see text]